(6 days)
Not Found
Not Found
No
The document describes a liquid chemistry control material for monitoring laboratory procedures, with no mention of AI or ML in its function or description.
No
The device is described as a chemistry control material for monitoring analytical procedures, not for treating patients.
No
Explanation: This device is a chemistry control material used for monitoring the accuracy and precision of lipid chemistry control material for monitoring automated analytical procedures. While it assists in the diagnosis and management of LDL cholesterol, it is not a diagnostic device itself; rather, it is used to ensure the reliability of diagnostic tests.
No
The device description is not found, but the intended use clearly describes a "ready-to-use, assayed chemistry control material" which is a physical substance, not software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that it is a "chemistry control material for monitoring the accuracy and precision of lipid chemistry control material for monitoring the automated analytical procedures." This indicates it is used in vitro (outside the body) to evaluate the performance of diagnostic tests.
- Purpose: It is used to "assist in the diagnosis and management of LDL cholesterol" and "assist in tisk patient populations." While it's a control material and not a diagnostic test itself, its purpose is directly tied to ensuring the reliability of diagnostic tests used for these clinical purposes.
- Care Setting: It is intended for use in a "Clinical Laboratory," which is the typical setting for performing in vitro diagnostic testing.
Control materials like this are essential components of the quality control process for IVD tests. They are used to verify that the analytical system is performing correctly and producing accurate results, which in turn supports the diagnostic process.
N/A
Intended Use / Indications for Use
Clinical Controls LiquiSPx Liquid Lipid control is a ready-to-use, assayed chemistry control material for monitoring the accuracy and precision of lipid chemistry control material for monitoring the assulting the automated analytical procedures. Lipid analysis consists of measuring total cholesterol, triglycerides, HDL and LDL cholesterol. It is used to assist in the diagnosis and management of LDL cholesterol. This dood to assist in tisk patient populations.
Product codes
JJY
Device Description
Not Found
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Not Found
Key Metrics
Not Found
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1660 Quality control material (assayed and unassayed).
(a)
Identification. A quality control material (assayed and unassayed) for clinical chemistry is a device intended for medical purposes for use in a test system to estimate test precision and to detect systematic analytical deviations that may arise from reagent or analytical instrument variation. A quality control material (assayed and unassayed) may be used for proficiency testing in interlaboratory surveys. This generic type of device includes controls (assayed and unassayed) for blood gases, electrolytes, enzymes, multianalytes (all kinds), single (specified) analytes, or urinalysis controls.(b)
Classification. Class I (general controls). Except when intended for use in donor screening tests, quality control materials (assayed and unassayed) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of an eagle with three lines representing its wings.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
AUG 3 0 2001
Mr. James F. Godfrey Official Correspondent, Regulatory Affairs Clinical Controls Division 12038 Centralia Road Suite C Hawaiian Gardens, CA 90716
Re: K012855
Trade/Device Name: LiquiSPx Liquid Lipid Control Regulation Number: 21 CFR 862.1660 Regulatory Class: I, reserved Product Code: JJY Dated: August 20, 2001 Received: August 24, 2001
Dear Mr. Godfrey:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
1
Page 2 -
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed nothleation. The I Dr I imating sification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and 1 IT you desire specific arriver diagnostic devices), please contact the Office of Compliance at additionally 607.10 for in This alagitestions on the promotion and advertising of your device, (2017) 594-1566. Fraunding at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small mormation on your responsibility on sumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Butman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
510(k) Number (if known): K012855
Device Name: LiquiSly Liquid Lipid Control
Indications For Use:
Clinical Controls LiquiSPx Liquid Lipid control is a ready-to-use, assayed Clinical Controls Liquior X Elquio Lipit Control and precision of lipid
chemistry control material for my the accuracy and precision of lipid chemistry control material for monitoring the assulting the automated analytical procedures.
Lipid analysis consists of measuring total cholesterol, triglycerides, HDL and Lipid analysis consists of measuring to the diagnosis and management of
LDL cholesterol. It is used to assist in the diagnosis and management of LDL cholesterol. This dood to assist in tisk patient populations.
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Kusia Alexander/for Joan Cooper
Division Sign-Off
(Division Sign-Oft)
Division of Clinical Laboratory Devices
510(k) Number K012855
Prescription Use √
(Per 21 CFR 801.109)
OR
Over-The-Counter Use _________________________________________________________________________________________________________________________________________________________
(Optional Format 1-2-96)